The Global Hemostatic Gels Industry, valued at US$ 957.1 million in 2021, is on a trajectory to reach an impressive US$ 1.9 billion by 2032, boasting a robust Compound Annual Growth Rate (CAGR) of 6.8%. This forecast comes from a comprehensive analysis conducted by Future Market Insights, a leading market intelligence and consulting firm.
The study indicates a significant market share dominance for porcine-based hemostatic gels, accounting for approximately 45% in 2021. This revelation underscores the increasing adoption of porcine-derived solutions, emphasizing their efficacy in hemostasis and overall market preference.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-15085
Globally, around 2,000,000 people die from hemorrhage each year, out of which approximately 1,500,000 deaths are due to trauma injuries. Similarly, every year almost 60,000 people die in the U.S. due to hemorrhaging and blood loss. These figures indicate the need for hemostatic gels during surgical procedures to improve clinical outcomes.
Key Takeaways:
- Based on product type, sales of porcine-based hemostatic gels are expected to grow at a 5.7% CAGR through 2032.
- In terms of indication, the cardiovascular surgery segment is expected to account for 33.1% of the total market share over the assessment period.
- By end user, demand for hemostatic gels across hospitals will increase at a 5.4% CAGR during the forecast period.
- The U.S. dominated the North America hemostatic gels market in 2021, holding 82% of the total market share.
- Demand for hemostatic gels in India is forecast to grow at a 7.4% CAGR over the assessment period.
- Sales in the U.K. hemostatic gels market are expected to increase at a 7.1% CAGR through 2032.
- China will emerge as a lucrative pocket, with demand growing at an 8% CAGR over the forecast period.
Speak to our Research Expert
https://www.futuremarketinsights.com/ask-question/rep-gb-15085
“Rising adoption of effective hemostatic gels across various industries for the protection of the workforce is expected to fuel demand in the market. In addition to this, rising awareness regarding the usage of hemostatic gels for blood loss management across emerging economies will augment the growth in the market,” says an FMI analyst
Clotting agents are medical devices used to stop bleeding in a variety of clinical settings, including surgical procedures, emergency situations, and trauma care. These gels work by promoting the clotting process, which is essential to prevent excessive blood loss.
Competition Landscape:
Key players operating in the Global Hemostatic Gels Industry are adopting strategies such as product launches, mergers & acquisitions, joint ventures, and R&D activities to improve their global presence. For instance:
- In 2019, Baxter International, Inc. introduced Floseal Hemostatic Matrix, its new hemostatic agent. Floseal Hemostatic Matrix U.S.FDA approved and is used to stop bleeding during surgical procedures.
- In 2021, Medcura, Inc. together with ASO LLC launched Rapid-Seal, a new class of antibacterial hemostatic gel. This product meets the market demand for a transparent gel that will be easily applied during surgeries.
Request Your Customized Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-15085
Global Hemostatic Gels Industry Key Companies Profiled:
- Baxter
- Bio-Chem LLC
- Clinician’s Choice Dental Products Inc.
- Cresilon, Inc.
- DSI Ltd.
- ENDOVISION CO., LTD
- Ethicon US, LLC
- F&A Medical
- PrevestDenPro
- Septodont
- Teleflex Incorporated
- Ultradent Products Inc. All
- VladMiVa
- Medcura, Inc.,
Key Market Segments Covered In Global Hemostatic Gels Industry Research
By Material:
- Bovine-Based
- Porcine-Based
- Polymer-Based
By Indication:
- General Surgery
- Dental Surgery
- Veterinary Surgery
- Cardiovascular Surgery
- Orthopaedic Surgery
- Others
Click Here To Buy Your Full Report
https://www.futuremarketinsights.com/checkout/15085
By End-User:
- Hospitals
- Specialty Clinics
- Veterinary Settings
- Ambulatory Surgical Centers
- Online Sales
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
